Introduction to the use of belatacept: A fusion protein for the prevention of post transplant kidney rejection

Biologics: Targets and Therapy

Volumn 6, Issue , 2012, Pages 355-362

  Ippoliti, Giovanbattista ^a,b   D'Armini, Andrea Maria ^b   Lucioni, Marco ^c   Marjieh, Mazen ^a   Viganò, Mario ^b  

^a UO Medicina Interna   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Belatacept; Costimulation; Organ transplantation

Indexed keywords

BASILIXIMAB; BELATACEPT; CD28 ANTIGEN; CD40 ANTIGEN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANEMIA; CHRONIC ALLOGRAFT NEPHROPATHY; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; FEVER; GRAFT SURVIVAL; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NEUTROPENIA; NONHUMAN; PERIPHERAL EDEMA; PNEUMONIA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RENAL PROTECTION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 84872259157     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S27565     Document Type: Review

References (43)

1. Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci U S A. 1999;96(1): 185-190.
2. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715-2729.
3. Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev. 2009;229(1):271-293.
4. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515-548.
5. Bromley SK, Iaboni A, Davis SJ, et al. The immunological synapse and CD28-CD80 interactions. Nat Immunol. 2001;2(12):1159-1166.
6. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol. 2001;1(3):220-228.
7. McAdam AJ, Schweitzer AN, Sharpe AH. The role of B7 costimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev. 1998;165:231-247.
8. Sharpe AH, Abbas AK. T-cell costimulation - biology, therapeutic potential, and challenges. N Engl J Med. 2006;355(10):973-975.
9. Greene JL, Leytze GM, Emswiler J, et al. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J Biol Chem. 1996;271(43):26762-26771.
10. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001;19:225-252.
11. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1(5):405-413.
12. van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol. 1997;9(3):330-337.
13. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16:111-135.
14. Shimizu K, Schönbeck U, Mach F, Libby P, Mitchell RN. Host CD40 ligand defciency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol. 2000;165(6):3506-3518.
15. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6(2):114.
16. Ford ML, Larsen C P. Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev. 2009;229(1): 294-306.
17. Schwartz RH. T cell energy. Annu Rev Immunol. 2003;21:305-334.
18. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA. 1997;94(16):8789-8794.
19. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233-258.
20. Larsen C P, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996;381(6581):434-438.
21. Larsen C P, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5(3): 443-453.
22. Emamaullee J, Toso C, Merani S, Shapiro AM. Costimulatory blockade with belatacept in clinical and experimental transplantation - a review. Expert Opin Biol Ther. 2009;9(6):789-796.
23. Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18-32.
24. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant. 2008;8(10):2086-2096.
25. Zhou Z, Shen J, Hong Y, Kaul S, Pfster M, Roy A. Time-varying belata-cept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients. Clin Pharmacol Ther. 2012;92(2):251-257.
26. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belata-cept in renal transplantation. N Engl J Med. 2005;353(8):770-781.
27. Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol. 2010;21(9): 1587-1596.
28. Latek R, Fleener C, Lamian V, et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation. 2009;87(6):926-933.
29. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10(3):535-546.
30. Adams AB, Pearson TC, Larsen C P. Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev. 2003;196:147-160.
31. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifcally with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111-122.
32. Pilat N, Sayegh MH, Wekerle T. Costimulatory pathways in transplantation. Semin Immunol. 2011;23(4):293-303.
33. Durrbach A, Prestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10(3):547-557.
34. Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation. 2011;91(9):976-983.
35. Larsen C P, Grinyó J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation. 2010;90(12):1528-1535.
36. Florman S, Becker T, Bresnahan B, et al. Three-year outcomes by donor type in phase III studies of belatacept vs cyclosporine in kidney transplantation (BENEFIT and BENEFIT-EXT). Am J Transplant. 2011;11 (Suppl S2):28-559 [Abstract 229].
37. Su VC, Harrison J, Rogers C, Ensom MH. Belatacept: a new biologic and its role in kidney transplantation. Ann Pharmacother. 2012;46(1): 57-67.
38. Martin ST, Tichy EM, Gabardi S. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation. Pharmacotherapy. 2011;31(4):394-407.
39. Ferguson R, Grinyó J, Vincenti F, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant. 2011;11(1):66-76.
40. Archdeacon P, Dixon C, Belen O, Albrecht R, Meyer J. Summary of the US FDA approval of belatacept. Am J Transplant. 2012;12(3): 554-562.
41. Ippoliti G, Rinaldi M, Pellegrini C, Viganò M. Incidence of cancer after immunosuppressive treatment for heart transplantation. Crit Rev Oncol Hematol. 2005;56(1):101-113.
42. NULOJIX® (belatacept) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2011. Available from: http://packageinserts.bms.com/pi/pi_nulojix.pdf. Accessed August 23, 2012.
43. Grinyó J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation. 2010;90(12):1521-1527.